Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Craig

Showing results (581-590 of 595) with videos related to

Pageof 60
Sort By:
Iscience|April 22, 2024
Erratum: iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cellsHabib Bouguenina, Stephanos Nicolaou, Yann-Vaï Le Bihan, et al.
The Hastings Center Report|December 9, 2022
Clarifying the Ethics and Oversight of Chimeric ResearchJosephine Johnston, Insoo Hyun, Carolyn P Neuhaus, et al.
Iscience|June 26, 2023
iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cellsHabib Bouguenina, Stephanos Nicolaou, Yann-Vaï Le Bihan, et al.
American Journal of Ophthalmology|November 23, 2025
TFOS DEWS IIIFiona Stapleton, Pablo Argüeso, Penny Asbell, et al.
American Journal of Ophthalmology|May 5, 2026
Corrigendum to "TFOS DEWS III: Digest" Am J Ophthalmol. 2025; 279:451-553Fiona Stapleton, Pablo Argüeso, Penny Asbell, et al.
American Journal of Ophthalmology|June 5, 2025
TFOS DEWS III: DigestFiona Stapleton, Pablo Argüeso, Penny Asbell, et al.
Journal of Medicinal Chemistry|November 30, 2021
Into Deep Water: Optimizing BCL6 Inhibitors by Growing into a Solvated PocketMatthew G Lloyd, Rosemary Huckvale, Kwai-Ming J Cheung, et al.
The Ocular Surface|July 25, 2017
TFOS DEWS II IntroductionJ Daniel Nelson, Jennifer P Craig, Esen K Akpek, et al.
Journal of Medicinal Chemistry|June 3, 2022
Optimizing Shape Complementarity Enables the Discovery of Potent Tricyclic BCL6 InhibitorsOwen A Davis, Kwai-Ming J Cheung, Alfie Brennan, et al.
Nature Chemical Biology|December 24, 2005
Monocarboxylate transporter MCT1 is a target for immunosuppressionClare M Murray, Raymond Hutchinson, John R Bantick, et al.
Pageof 60

Showing results (581-590 of 595) with videos related to

Sort By:
Pageof 60
Iscience|April 22, 2024
Erratum: iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cellsHabib Bouguenina, Stephanos Nicolaou, Yann-Vaï Le Bihan, et al.
The Hastings Center Report|December 9, 2022
Clarifying the Ethics and Oversight of Chimeric ResearchJosephine Johnston, Insoo Hyun, Carolyn P Neuhaus, et al.
Iscience|June 26, 2023
iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cellsHabib Bouguenina, Stephanos Nicolaou, Yann-Vaï Le Bihan, et al.
American Journal of Ophthalmology|November 23, 2025
TFOS DEWS IIIFiona Stapleton, Pablo Argüeso, Penny Asbell, et al.
American Journal of Ophthalmology|May 5, 2026
Corrigendum to "TFOS DEWS III: Digest" Am J Ophthalmol. 2025; 279:451-553Fiona Stapleton, Pablo Argüeso, Penny Asbell, et al.
American Journal of Ophthalmology|June 5, 2025
TFOS DEWS III: DigestFiona Stapleton, Pablo Argüeso, Penny Asbell, et al.
Journal of Medicinal Chemistry|November 30, 2021
Into Deep Water: Optimizing BCL6 Inhibitors by Growing into a Solvated PocketMatthew G Lloyd, Rosemary Huckvale, Kwai-Ming J Cheung, et al.
The Ocular Surface|July 25, 2017
TFOS DEWS II IntroductionJ Daniel Nelson, Jennifer P Craig, Esen K Akpek, et al.
Journal of Medicinal Chemistry|June 3, 2022
Optimizing Shape Complementarity Enables the Discovery of Potent Tricyclic BCL6 InhibitorsOwen A Davis, Kwai-Ming J Cheung, Alfie Brennan, et al.
Nature Chemical Biology|December 24, 2005
Monocarboxylate transporter MCT1 is a target for immunosuppressionClare M Murray, Raymond Hutchinson, John R Bantick, et al.
Pageof 60